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Abstract
Background: Information on the neonatal exposure to excipients is limited. Our aim was to describe the extent of
excipient intake by Estonian neonates; to classify the excipients according to potential neonatal toxicity and thereby
to measure the extent of exposure of neonates to potentially harmful excipients.
Methods: A prospective cohort study that recorded all medicines prescribed to patients aged below 28 days
admitted to Tartu University Hospital from 01.02-01.08 2008 and to Tallinn Children’s Hospital from 01.02- 01.08
2009 was conducted. Excipients were identified from Summaries of Product Characteristics and classified according
to toxicity following a literature review.
Results: 1961 prescriptions comprising 107 medicines were written for 348/490 neonates admitted. A total of 123
excipients were found in 1620 (83%) prescriptions and 93 (87%) medicines. 47 (38%) of these excipients were
classified as potentially or known to be harmful to neonates. Most neonates (97%) received at least one medicine
(median number 2) with potentially or known to be harmful excipient. Parabens were the most commonly used
known to be harmful excipients and sodium metabisulphite the most commonly used potentially harmful
excipient, received by 343 (99%) and 297 (85%) of treated neonates, respectively.
Conclusions: Hospitalised neonates in Estonia are commonly receiving a wide range of excipients with their
medication. Quantitative information about excipients should be made available to pharmacists and neonatologists
helping them to take into account excipient issues when selecting medicines and to monitor for adverse effects if
administration of medicines containing excipients is unavoidable.
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Background
Excipients are essential components of medicinal pro-
ducts required for manufacturing processes to assure
several properties such as solubility, bioavailability and
stability of the final dosage form. Concerns about the
safety of pharmaceutical excipients are growing due to
the increasing number of adverse reports, especially in
neonates [1-4]. According to regulatory requirements,
excipients have to be appropriately evaluated for safety
[5-7]. Similar to active pharmaceutical ingredients, in
most instances the safety data of excipients is based on
adult exposure. Thus, information about their accept-
ability and safety in relation to the age and development
status of the child is often lacking [8].
Neonates are the most vulnerable patient population
when adverse reactions of excipients are considered.
This is mainly due to organ immaturity and differences
in pharmacokinetic (PK) and pharmacodynamic (PD)
profiles compared to adults [9]. The inclusion of inad-
equately studied excipients in products used in neonates
has resulted in tragedies such as the E-ferol incident
where over 30 infants died after receiving an intravenous
vitamin E product containing polysorbate 80 [10]. The
potential for dose-related adverse reactions of excipients
are of particular concern in preterm infants due to the
immaturity of hepatic and renal functions [11,12].
The use of potentially toxic excipients in medicines
given to neonates is not rare [13] as they are present in
many commonly used drug products [14,15]. However,
neonatal exposure to excipients is still poorly studied. Pre-
vious studies have been selective in terms of populations,
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indications or excipients. For example, the studies have
included premature neonates only [13] or have been
restricted to medicinal products used in gastroenterology
[14] or to excipients known to be toxic (sodium benzoate,
propylene glycol, methyl- and propyl parahydroxybenzo-
ate, saccharin sodium, benzyl alcohol, benzalkonium
chloride, polysorbate 80 and ethanol) [13,16]. We are not
aware of studies looking at frequency of excipient use in
an unselected cohort of hospitalised neonates.
Our objectives were first, to record the frequency of
using potentially harmful excipients in hospitalised neo-
nates; second, to classify the excipients used in neonatal
wards in Estonia into categories according to the pos-
sible toxicity to neonates; and third, to describe how
many neonatal prescriptions included potentially harm-
ful excipients.
Methods
This study used a cohort design recruiting in two cen-
tres over two non-overlapping but equivalent periods. A
total of four wards in both paediatric hospitals of Estonia
participated. All medicines prescribed to hospitalised
neonates with postnatal age (PNA) below 28 days were
recorded in Tartu University Hospital (TUH) from 1st of
February to 1st of August 2008 and in Tallinn Children’s
Hospital (TCH) from 1st of February to 1st of August
2009 [17]. The following information was extracted from
the hospital records on twice weekly visits: demographic
data (gestational age [GA], birth weight, gender, date of
birth, PNA), admission and discharge dates and pre-
scriptions for all medicinal products (International Non-
proprietary and product names, formulations). The dose
and frequency of medicines were not recorded for the
purpose of this study and the use of standard intravenous
replacement solutions, nutritional and technical products
(including contrast agents), basic creams and ointments,
parenteral nutrition solutions, vaccines and vitamins were
excluded, although we acknowledge that some of these
products may also contribute to the general excipient
exposure.
The data from the neonatal wards at both hospitals were
pooled and patients categorised based on the GA as pre-
term (<37 weeks) and full term (≥37 weeks) neonates.
The excipients present in the prescribed medicines
were identified from their Estonian Summaries of Product
Characteristics (SPC) and if the drug product was not
registered in Estonia in September 2009, from the
package insert leaflets. The excipients were divided into
four categories as detailed in Table 1. The following lit-
erature sources were used for classification: Rowe’s
Handbook of Pharmaceutical excipients 6th ed. [18],
European Commission guidelines on the excipients in
the label and package leaflet of medicinal products for
human use [19], European Medicines Agency (EMA)
reflection paper formulations of choice for the paediat-
ric population, 2006 [8], article by Fabiano et al. [20]
and book from Costello et al. [21]. A PubMed database
search was conducted by using the name of each ex-
cipient AND/OR synonyms AND “human toxicity” as
search terms; no other limiters or terms were used to
narrow or widen the search. If there were no results in
the PubMed search or other abovementioned informa-
tion sources, Google scholar (http://scholar.google.com;
last accessed 24th September 2011) search was con-
ducted using the same search terms.
In this study, all excipients for which according to the
abovementioned sources there were some safety concerns
were classified as “potentially harmful” (Category 2 in
Table 1).
The study was approved by the Ethics Review Committee
of the University of Tartu. The study used anonymised data
collected in routine clinical practice and did not require
individual consent of the parent.
Results
There were a total of 490 neonates (203 in TUH and
287 in TCH) hospitalised during the two study periods.
Of these, 348 (176 preterm) received 1961 prescriptions
for 107 medicines. Parenteral formulations were used
most often (61/107) followed by manipulated oral solid
formulations such as crushed tablets or opened capsules
(19/107). Oral liquids (8/107), topical ointments and
creams (6/107), ophthalmic (5/107), rectal (4/107) and
inhalation (4/107) medicines were rarely used. In total
93 of 107 medicines (87%) and 1620 of 1961 prescrip-
tions (83%) contained at least one excipient. The total
number of different excipients was 123.
Classification of excipients and neonatal exposure
One third of excipients (47/123) were classified as poten-
tially harmful (Category 2, Table 1), including eight excipi-
ents already known to be harmful in neonates (Table 2).
Another third of excipients (42/123) were classified as po-
tentially safe (Category 1, Table 1). For the remaining 34
excipients human safety / toxicity data was not found in
the literature (19/34; Category 3) or the description in
the SPC was too unspecific to conduct a literature
search (15/34; Category 4), Table 1. Many flavouring
agents (e.g. banana and strawberry flavour) and essential
oils (e.g. orange essential oil) had to be classified to the
latter group as their chemical entity was not described in
the SPC.
Almost all treated neonates (339/348; 97%) received
medicines with at least one potentially harmful excipient
and as many as 88% (307/348) received at least one of
the eight excipients known to be harmful in neonates
(Table 2). From the medicines prescribed, the median
number of included excipients known to cause harm in
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neonates was two (interquartile range (IQR) 5–2; pre-
term neonates median of 3, range 1 to 15, IQR 4–2;
term neonates median of 1, range 1 to 11, IQR 3–1).
Potentially and known to be harmful excipients in
medicines used in neonates
Figure 1 illustrates that approximately two thirds (73 /107,
68%) of all the medicines used in neonates contained at
least one potentially harmful or known to be harmful
excipient. The median number of such excipients per
medicinal product was two and maximum was five (in
simeticone oral suspension). The proportion of medicines
containing potentially harmful excipients in preterm neo-
nates was even higher than the general rate - 77%. When
preterm and term neonates were compared in terms of
medicines with potentially safe excipients the percentage
of such medicines was the same in both groups (22%).
The detailed characteristics of excipients and their
potential safety issues are described in Table 3.
The most common excipients that are known to cause
harm were propylene glycol and ethanol, both present in
seven products. In relation to prescription frequency,
the most common excipients known to cause harm were
parabens (methyl- and propylparahydroxybenzoate) used
as preservatives in parenteral gentamicin given to 57% of
treated neonates. The gentamicin product also included
another potentially harmful excipient, namely sodium
metabisulphite (Table 4).
Simeticone oral suspension was the second most com-
monly prescibed medicine, given to 31% of neonates. The
simeticone product contained two excipients known to
cause harm – saccharin sodium and sodium benzoate, and
also three other potentially harmful excipients - colloidal
anhydrous silica, sorbic acid and sodium cyclamate
(Table 4).
Of excipients known to cause harm as an excipient in
older age groups, but where there is no neonatal data, col-
loidal anhydrous silica and anhydrous sodium hydrogen
phosphate were most commonly present, both in 10 medi-
cines. Medicines containing sodium metabisulfite were pre-
scribed most frequently in this category. Again its frequent
exposure was driven by wide use of parenteral gentamicin.
Approximately two thirds of parenterally used products
(29/47) contained some potentially harmful excipient. The
situation was even worse for other formulations - all of
the prescribed rectal, topical, inhalation, oral solutions
and oral suspensions contained at least one potentially
harmful excipient. The use of topical agents in neonates
was rare and only 8/33 products contained excipient
known to be toxic to neonates. Only one of the 19 orally
administered solid drug formulations and one of the five
ocular formulations were free of potentially harmful exci-
pients. Not surprisingly, most of medicines free from po-
tentially harmful excipients were parenteral single-dose
antibacterial or antifungal formulations (13/ of all the 35
medicines without harmful excipients).
A total of 19 medicines were licensed for use in neonates
(6 for preterm and all for term neonates). Approximately
half of them (3/6 in preterm and 8/19 in term neonates)
contained at least one potentially harmful excipient.
The amount of the excipients in the drug formulation
was present in the SPCs for only two medications (meto-
clopramide injection solution and esomeprazole powder
for injection).
Discussion
To the best of our knowledge this is the first study look-
ing at the excipients in medicines given to an unselected
group of hospitalised neonates. We describe the pres-
ence of over a hundred different excipients and demon-
strate that almost all drugs used in neonates (including
those licensed for neonates) contain at least one poten-
tially harmful excipient. The safety of the majority of
these excipients in neonates is not easily assessable as
the information in the SPCs is scarce and published
studies on the topic are rare. The fact that over a third
of excipients present in medicines are known or sug-
gested to be potentially harmful to neonates is even
more worrisome.
As we are not aware of any validated classification of
excipients in terms of neonatal safety and tolerability, we
created a tentative classification for the study purposes in
which all administered excipients were divided into the
categories by conducting a literature search. As a result
Table 1 Classification of excipients to which studied neonates were exposed according to available safety data†
Category Safety status Description No of excipients identified
1 Potentially safe No adverse reactions reported 42
2 Potentially harmful and known to be harmful Adverse reactions reported 47
3 No safety data found No data found in the literature on human
exposure and toxicity
19
4 Description of the excipient in SPC or PIL unspecific Description does not allow a specific literature search 15
Total 123
SPC- summary of product characteristics.
PIL - package insert leaflet.
†Based on data from Refs [8,18-21], and PubMed searches.
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Table 2 Excipients identified as known to be harmful and potentially harmful and the prescribing prevalence of
medications containing them in studied neonates
Excipient} No of medications containing /
Total Number of prescriptions
Medications containing excipients (number of prescriptions†)
Known to be harmful to neonates
Parabens (methyl- and propyl
parahydroxybenzoate)
6 / 343 Gentamicin inj (200), heparin inj (86), iron oral solution (32), heparin sodium
ointment (12), prednisolone inj (7), cetirizine oral solution (6)
Saccharin sodium 6 / 173 Simeticone oral suspension (108), iron oral solution (32), zidovudine oral solution
(17), cetirizine oral solution (6), miconazole ointment (6), sultamicilline powder for
suspension (4)
Sodium benzoate 4 / 156 Simeticone oral suspension (108), caffeine solution (29), zidovudine oral solution
(17), fludrocortisone inj (2)
Benzyl alcohol 6 / 125 Heparin inj (86), hydrocortisone inj (23), phenobarbital inj (13), clotrimazole
ointment (1), diazepam rectal suspension (1), diclofenac inj (1)
Benzalkonium chloride 6 / 104 Salbutamol nebulisation solution (54), chloramphenicol ophthalmic solution (29),
fusidic acid opthalmic solution (16), troxerutin gel (3), ipratropium bromide
nebulisation solution (1), dexamethasone+ neomycin + polymyxin B opthalmic
solution (1)
Propylene glycol 7 / 79 Salbutamol nebulisation solution (54), phenobarbital inj (13), cetirizine oral
solution (6), diazepam oral solution (3), ibuprofen tablet (1), diclofenac inj (1),
diazepam rectal solution (1)
Polysorbate 80 4 / 70 Budesonide nebulisation solution (31), chloramphenicol ophalmic solution (29),
miconazole ointment (6), tobramycin opthalmic ointment (4)
Ethanol 7 / 31 Heparin sodium ointment (12), miconazole ointment (6), dinoprostone inj (5),
Lipase + amylase + protease tablet (3), diazepam oral solution (3), diosmectide
powder for oral suspension (1), alprostadil inj (1)
Potentially harmful excipients
Sodium metabisulphite 6 / 297 Gentamicin inj (200), dobutamine inj (45), epinephrine inj (36), morphine inj (14),
diclofenac inj (1), norepinephrine inj (1)
Silica, colloidal anhydrous 10 / 195 Simeticone oral suspension (108), phenobarbital tablet (29), hyoscine
butylbromide tablet (20), spironolactone tablet (18), furosemide tablet (6),
ursodeoxycholic acid tablet (5), sotalol tablet (4), propranolol tablet (3),
diosmectide powder for oral suspension (1), ibuprofen tablet (1)





10 / 122 Paracetamol suppository (29), paracetamol infusion solution (24), hydrocortisone
powder for infusion solution (23), epoetin beta inj (22), dexamethazone inj (8),
oxacillin powder for infusion solution (7), sultamicillin powder for infusion
solution (4), ranitidine inj (2), pentoxifylline inj (2), ipratropium bromide
nebulisation solution (1)
Sodium cyclamate 1 / 108 Simeticone oral suspension (108)
Disodium edetate 10 / 106 Budesonide nebulisation solution (31), piperacillin + tazobactam inj (25), fusidic
acid ophthalmic solution (16), metoclopramide inj (10), dexamethazone inj (8),
sulphametizole opthalmic solution (6), aminophylline inj (4), troxerutin ointment
(3), esomeprazole inj (2), acetylcysteine inj (1)
Gelatin 5 / 51 Phenobarbital tablet (29), hydrochlorothiazide tablet (10), ursodeoxycholic acid
tablet (5), digoxin tablet (4), lipase + amylase + protease tablet (3)
Sodium bicarbonate 4 / 44 Meropenem inj (32), povidone-iodine ointment (8), ceftazidime powder for
infusion solution (3), enalapril tablet (1)
Boric acid 2 / 33 Chloramphenicol opthalmic solution (29), tobramycin opthalmic solution (4)
Borax 1 / 29 Chloramphenicol opthalmic solution (29)
Macrogols - polyethylene
glycol
5 / 25 Povidone-iodine ointment (8), pentoxifylline tablet (7), Hydrocortisone +
chlorhexidine ointment (4), lipase + amylase + protease tablet (3), propranolol
tablet (3)
Trometamol 2 / 25 Ibuprofen inj (21), tobramycin ophthalmic ointment (4)
Glycine 1 / 22 Epoetin beta inj (22)
Calcium chloride dihydrate 1 / 22 Epoetin beta inj (22)
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we show, that in addition to excipients known to cause
harm (e.g. propylene glycol, ethanol etc.), many other exci-
pients (e.g. sodium metabisulfite and colloidal anhydrous
silica) could possess some safety concerns to neonates as
they have been found to be harmful in older children and
adults (Table 3).
The proportion of medicines containing potentially
harmful excipients in our study (68%) is higher than the
Figure 1 Proportion of prescribed medications, containing at least one excipient, in each safety category (every drug is listed once
according to the worst-case scenario - into the most harmful category).
Table 2 Excipients identified as known to be harmful and potentially harmful and the prescribing prevalence of
medications containing them in studied neonates (Continued)
Leucine 1 / 22 Epoetin beta inj (22)
Titanium dioxide 5 / 21 Pentoxifylline tablet (7), ursodeoxycholic acid tablet (5), lipase + amylase +
protease tablet (3), propranolol tablet (3), sildenafil tablet (3)
Povidone 4 / 19 Pentoxifylline tablet (7), furosemide tablet (6), drotaverine tablet (5), teophylline
tablet (1)
Trolamine 2 / 15 Heparin sodium ointment (12), troxerutin ointment (3)
Cresol 1 / 11 Diosmectide powder for oral suspension (1)
Maltose 2 / 7 Tobramycin ophthalmic ointment (4), immunoglobuline inj (3)
Erythrosine 1 / 7 Pentoxifylline tablet (7)
Benzethonium chloride 1 / 7 Ketamine inj (7)
Sodium acetate trihydrates 2 / 7 Cetirizine oral solution (6), flecainide inj (1)
Cetostearyl alcohol 2 / 5 Hydrocortisone + chlorhexidine ointment (4), clotrimazole ointment (1)
Ethylendiamine 1 / 4 Aminophylline inj (4)
Macrogol cetostearyl ether 1 / 4 Hydrocortisone + chlorhexidine ointment (4)
Sodium laurilsulfate 1 / 3 Lipase + amylase + protease tablet (3)
Lactic acid 1 / 3 Milrinone inj (3)
Copovidone 1 / 3 Propranolol tablet (3)
Sodium formaldehyde
sulfoxylate
2 / 2 Diazepam rectal solution (1), diclofenac inj (1)
Castor oil 1 / 1 Teophylline tablet (1)
Sorbitan stearate 1 / 1 Clotrimazole ointment (1)
Acacia 1 / 1 Diosmectide powder for oral suspension (1)
}European Pharmacopoeia names were used for excipients.
† Pooled data from Tartu University Hospital (February - August 2008) and Tallinn Children’s Hospital (February - August 2009).
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Table 3 Excipients known to be harmful and potentially harmful to neonates used in study population, their
applications and safety concerns
Excipient Functional category† Applications and typical concentration
ranges†
Safety concern
Known to be harmful to neonates
Parabens (methyl- and propyl
parahydroxybenzoate)
Antimicrobial Antimicrobial activity against yeasts and
molds. Combination of Methyparaben
(0.18%) and propylparaben (0.02%) for
parenteral formulations. In combinations
with propylene glycol (2-5%)/ imidurea
Hyperbilirubinemia in neonates. Irritant in
injections / ophthalmic drugs.
Hypersensitivity reactions. [18,19]
Saccharin sodium Sweetening 0.02-0.5% w/w* Urticaria with pruritus and photosensitivity
reactions. [14]
Sodium benzoate Antimicrobial, tablet /
capsule lubricant
0.02-0.5% in oral medicines; 0.5% in
parenteral medicines; 2-5% w/w tablet
lubricant
Contact urticaria. [21] Topical irritant.
Increased risk of hyperbilirubinaemia in
neonates.
Benzyl alcohol Antimicrobial, solvent Up to 2% v/v* in parenteral/oral
preparations, typically 1% v/v. 5% v/v and
up used as solubilisers. 10% v/v local
anaesthetic properties (parenterals,
ophthalmic solutions, oitments)
Headache, vertigo, nausea, vomiting,
diarrhea, metabolic acidosis, seizures,
gasping. Hypersensitivity; fatal toxic





Ophthalmic preparations – preservative,
0.01-0.02% w/v*; In combination with other
preservatives
Ototoxic when applied to ear, skin irritation
and hypersensitivity Bronchoconstriction in






Humectant – topical – approx.15%.
Preservative –solutions / semisolids – 15-
30%. Solvent or cosolvent: aerosol solutions
10-30%, oral solutions 10-25%, parenterals
10-60%, topical 5-80%
Skin irritation. Central nervous system (CNS)
depression. High doses - cardiovascular,





Emulsifying: alone in oil-in-water emulsions
1-15%; in combination 1-10%. To increase
water-holding prop of ointments 1-10%.
Solubilising: poorly soluble API*s in lipophilic
bases 1-5%; insoluble APIs in lipophilic bases
0.1-3%
E-Ferol syndrome - thrombocytopenia, renal
dysfunction, hepatomegaly, cholestasis,
ascites, hypotension, metabolic acidosis. [18]
Ethanol Solvent In the USA, the max quantity of alcohol
included in over the counter (OTC)
medicines 0.5% v/v for products for use by
children under 6 years of age. Parenteral
products containing up to 50% of alcohol
(e 95 or 96% v/v)
CNS depression - muscle incoordination,
visual impairment. Negative synergic effects
on CNS when associated with




Antioxidant in oral, parenteral, and topical
formulations: 0.01–1.0% w/v, intramuscular
27% w/v. Antimicrobial: syrups.
Hypersensitivity. Paradoxical bronchospasm,
wheezing, dyspnoe and chest tightness in
asthmatic children.[18-20]






Improves flow properties of dry powders
(0.1-0.5%) (tabletting); stabilizes emulsions
(1.0-5.0%); thixotropic thickening/
suspending (2.0-10.0%); in aerosols to
promote particulate suspension, eliminate
hard settling, minimize clogging of spray
nozzles (0.5-2.0%)






Buffering agent; sequestering agent.
Concentrations are dependent on the
formulation.
Gastrointestinal (GI) disturbances including
diarrhea, nausea, and vomiting [18]
Sodium bicarbonate Alkalizing; therapeutic. To produce or maintain an alkaline pH in a
preparation









High molecular weight macrogols can be
used as lubricants in tablet formulations;
water solubility and bad penetration
through skin makes them useful as
ointment bases
Hypersensitivity reactions, hyperosmolarity,
metabolic acidosis, and renal failure in burn
patients. [18]
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Table 3 Excipients known to be harmful and potentially harmful to neonates used in study population, their
applications and safety concerns (Continued)
Trometamol Buffering Buffering agent, buffer range from 7.1–9 Hypersensitivity reactions. [23]
Cetostearyl alcohol Emollient; emulsifying;
viscosity-increasing.
Increasing viscosity; stabilizes emulsions;










Tablet lubricant (1.0-2.0%) Irritation to the skin, eyes, mucous






When used alone produces water-in-oil
emulsions / microemulsions. In combination
with polysorbate produces water-in-oil or
oil-in-water emulsions / creams.
Hypersensitive reactions.[18]
Lactic acid Acidulant In injections in the form of lactate as a
source of bicarbonate (0.012-1.16%)
Neonates have difficulty in metabolizing R-
lactic acid, and this isomer and the
racemate should therefore not be used in
infants aged less than 3 months old. [18]
Sodium cyclamate Sweetening 0.17% w/v as sweeter, in combination with
saccharin
Photosensitivity. [18]
Disodium edetate Chelating Forms stable water-soluble complexes with
alkaline earth and heavy-metal ions;
concentrations 0.005-0.1%





Tablet binder; microencapsulation Local irritation. Hypersensitivity reactions,






Binder in wet-granulation process; coating;
solubilizer for poorly soluble drugs (0.5-5%)
Subcutaneous granulomas at the injection
site. [21]
Trolamine Alkalizing; emulsifying When mixed in equimolar proportions with
a fatty acid an emulsifying agent to produce
fine-grained, stable oil-in-water emulsions
will be formed (2-4%)




Antimicrobial preservative in parenteral
formulations (0.15-0.3%)
Skin hypersensitivity reactions. [18]
Maltose Sweetening; tablet
diluent
Osmotic - ophthalmic drops and parenteral
inf.
Single report of hyponatremia in a liver
transplantation patient. [18]




As antimicrobial preservative in eye drops.
Good buffering capacity to control pH.
Poisoning - abdominal pain, vomiting,
diarrhea, erythematous rash, CNS
depression. Convulsions, hyperpyrexia, and





Antimicrobial preservative in eye
preparations
Vomiting, diarrhea, erythema, CNS




Cofreeze-dried excipient in injectable
formulations
Disturbances of fluid and electrolyte
balance; cardiovascular and pulmonary
disorders. [18]
Calcium chloride dihydrate Antimicrobial, water-
absorbing.




As antiadherent to improve the
deagglomeration
Moderately toxic by the s/c route.[18]
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one recently published by van Riet-Nales et al. [28] in the
Netherlands (52% of oral liquid formulations and 7% of all
parenteral products). This difference is most likely
explained by the methodological variations, regional char-
acteristics in marketed product ranges and by differences
in classifying excipients into the toxicity categories. In the
Dutch study only “known to be toxic” excipients were
taken into the analysis while in our study a very conserva-
tive approach was taken and the excipients were classified
into the “potentially harmful” category even if only some
data on human toxicity had been published (also when
used as a substance) as one could not assure that the same
agent does not cause any harm when used in small quan-
tities as an excipient. However, we declare that all classifi-
cations without clear data from appropriately designed
studies are hypothetical.
The use of excipients is unavoidable. Some can be found
in food and WHO has set an acceptable daily intake for
several of these. Nevertheless the amount of excipients in
drug formulations is rarely reported in the SPCs making
the evaluation of precise exposure and assessment of true
harmfulness of these substances to neonates impossible.
Investigators have requested information about exact
excipient amounts from the manufacturers [13], but this is
very time-consuming and does not allow a large number of
medicines to be investigated. Whilst the FDA provides an
online database of excipient concentrations in licensed
medicines, it does not identify the marketed medicinal pro-
ducts for confidentiality reasons (http://www.accessdata.fda.
gov/scripts/cder/iig/getiigWEB.cfm; last accessed 14th Janu-
ary 2012). The limits on data about excipients are exempli-
fied by the 24 products (22% of the total used), which were
not officially registered in Estonia or through the centra-
lised EU mutual recognition agreement. These medicines
were imported to Estonia according to the ad hoc approval
of the Estonian State Agency of Medicines. The list of these
drugs included parenteral phenobarbital, petidine and so-
dium oxybutyrate. The SPCs of most of these products
could not be accessed, as they did not have European SPCs.
The lack of quantitative data despite considerable effort to
obtain information from the manufacturers means that our
results may underestimate the extent of excipient exposure
in these patients. However, this does not affect our conclu-
sions. We suggest that quantitative information about high-
risk excipients should be made available to pharmacists and
physicians working with neonates.
Table 3 Excipients known to be harmful and potentially harmful to neonates used in study population, their
applications and safety concerns (Continued)
Titanium dioxide Coating as opacifier,
pigment
As a white pigment and opacifier Possibly carcinogenic [24]
Benzethonium chloride Surfactant, antiseptic,
wetting and/or
solubilizing




synthetic coal tar dye
Dye Toxic to human lymphocytes in vitro, binds
directly to DNA. [26]
Sodium cetate trihydrate Antimicrobial;
buffering; flavoring,
stabilizing
As a buffering agent and as an antimicrobial
preservative
Poisonous if injected i/v, an irritant to the
skin and eyes. [18]
Ethylendiamine Counter ion Counter ion of theophylline Hypersensitivity reactions [27]
Macrogol cetostearyl ether Emulsifying;
penetration enhancer;
solubilizing; wetting






As a film-forming agent (0.5-5%); tablet
binder (direct compression and wet
granulation) (2.0-5.0%)




Antioxidant Antioxidant in parental, rectal solutions Moderately toxic by ingestion, when heated
to decomposition it emits toxic fumes. [18]
Castor oil Emollient; oleaginous
vehicle; solvent.






Viscosity increasing agent (as it is in powder
for oral suspensions)
Hypersensitivity reactions. [18]
* w/w – weight in weight.
v/v – volume in volume.
w/v – weight in volume.
API – active pharmacutical ingredient.
† Source: Ref [18].
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Despite the lack of quantitative information, it could be
that even if the excipient is known to be harmful, the daily
intake will not exceed the toxic threshold due to the small
quantities used in drug formulations. For example, from
using a parenteral gentamicin product, a premature infant
weighting 500 g and receiving a daily dose of 2 mg gets a
maximum of 0.1mcg of parabens (methyl- and propylpara-
hydroxybenzoate, parenteral formulations contain up to
0.75% parabens). When comparing this value to the
allowed daily intake of 10 mg/kg body weight in adults it
is obvious that the quantities are far below the toxic
threshold. However, the fact that in neonates organs and
thus the PK pathways are not fully matured may change
the situation drastically [20]. Furthermore Allegaert et al.
showed recently that a short duration of unintended pro-
pylene glycol administration at a median dose of 34 mg/kg
over 48 hours was well tolerated by (pre)term neonates
[29]. At the same time the authors stress that long-term
safety of propylene glycol is still not established. We be-
lieve that the well-known toxic or potentially harmful
excipients need careful safety assessment and determin-
ation of PK/PD profiles in neonates.
It has been stated that certain colouring and flavouring
agents such as erythrosine (cherry-pink dye) need to be
avoided in children [30]. This study also found that the
SPC description of 15 excipients was too unspecific to
allow a safety evaluation. Many of these excipients were
flavouring agents such as banana flavour, cherry aroma,
strawberry, raspberry flavour etc. Without further infor-
mation in the SPC the safety assessment and critical
evaluation of the administration of these agents to neo-
nates is impossible in clinical practice.
Table 4 Most commonly prescribed medicines (received by >10 patients) containing known to be harmful or
potentially harmful excipients
Rank Active substance, drug formulation No of prescriptions Potentially harmful or known to be harmful excipients
1 Gentamicin, inj solution 200 Parabens, sodium metabisulphite
2 Simeticone, oral suspension 108 Sodium benzoate, saccharin sodium, silicium dioxide, sodium
cyclamate, sorbic acid
3 Heparin, inj solution 86 Benzyl alcohol, parabens
4 Laurilsulphate + Sorbitol + Sodium citrate, rectal solution 60 Sorbic acid
5 Salbutamol, nebulisation solution 54 Benzalkonium chloride, propylene glycol
6 Dobutamine, inj solution 45 Sodium metabisulphite
7 Epinephrine, inj solution 36 Sodium metabisulphite
8 Iron, oral solution 32 Parabens, saccharin sodium
9 Budesonide, nebulisation solution 31 Polysorbate 80, disodiumedetate
10 Chloramphenicol, opthalmic solution 29 Benzalkonium chloride, polysorbate 80, borax, boric acid
11 Caffeine, solution 29 Sodium benzoate
12 Phenobarbital, tablet 29 Silicium dioxide, gelatin
13 Paracetamol, suppository 29 Disodium hydrogen phosphate
14 Piperacillin + tazobactam, inj solution 25 Disodium edetate
15 Paracetamol, inj solution 24 Disodium hydrogen phosphate
16 Hydrocortisone, inj solution 23 Benzyl alcohol, disodium hydrogen phosphate
17 Epoetin beta, inj solution 22 Disodium hydrogen phosphate, glycine, calcium chloride
dihydrate, leucine,
18 Ibuprofen, inj solution 21 Trometamol
19 Hyoscine butylbromide, tablet 20 Silicium dioxide
20 Spironolactone, tablet 18 Silicium dioxide
21 Zidovudine, oral solution 17 Sodium benzoate, saccharin sodium
22 Fusidic acid, ophthalmic solution 16 Benzalkonium chloride, disodium edetate
23 Morphine, inj solution 14 Sodium metabisulphite
24 Phenobarbital, inj solution 13 Benzyl alcohol, propylene glycol
25 Heparin sodium, topical gel 12 Parabens, ethanol, trietanolamine,
26 Insulin, inj solution 11 Cresol
Inj - injection.
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We found that the formulation of the most commonly
used drug in Estonian neonates, gentamicin, contains
well-known harmful excipients – parabens. However a
paraben-free gentamicin product is also registered in
Europe. With this our data are in line with van Riet-
Nales et al. [28] who also showed that for 22% of oral li-
quid paediatric medicines contain potentially harmful
excipients an alternative formulation lacking such excipi-
ent was available with the same active chemical entity.
This indicates that health professionals have a low
awareness on safety of excipients. We recommend that
when compiling a formulary for the treatment of vulner-
able patients such as neonates attention should also be
paid to the identification of excipients in medicines.
Limitations
The most important limitation of our study is the lack of
information on the exact amounts of excipients in medi-
cines which precludes us making any conclusions on the
real excipient exposure. This limitation was beyond our
control because manufacturers do not disseminate this in-
formation. The other challenges are the use of a novel and
non-validated classification system and restriction of the
study to one country only. Also we did not collect infor-
mation about dosage regimens since this would have been
uninterpretable in the absence of quantitative information
about the excipient content of the prescribed medicines.
Another issue, possibly characteristic of other small mar-
kets, was the significant use (22%) of unlicensed medicines
and thus unavailability of SPCs. In these cases the excipi-
ent content was recorded according to the package insert
leaflets. Altough we appreciate that only excipients of
intravenous, topical and opthalmic products and known
to be toxic excipients have to be declared in the package
leaflet, we assume that this will not significally affect our
conclusions. Finally the study was conducted in a small
country and thus these results cannot be generalised to
other countries. These limitations do not undermine our
findings that neonates are frequently exposed to a range of
potentially harmful and known to be toxic excipients.
Many of these limitations will be addressed in a recently
commenced international research project, the European
Study of Neonatal Excipient Exposure (ESNEE) [31],
which evaluates the neonatal excipient exposure of over
20 European countries. The aims of the project are to
show which excipients are used in formulations given to
neonates treated in European hospitals, to conduct a re-
view of toxicological studies on excipients and to investi-
gate excipient kinetics during treatment with commonly
prescribed neonatal medicines.
Conclusion
Hospitalised neonates commonly receive numerous exci-
pients, several of which have not until now been discussed
regarding their potential harm to neonates. There is an
urgent need for the careful toxicological assessment of
excipients as the information in the published literature is
limited. Information about excipients should be made
available to pharmacists and neonatologists to assist the
selection of the most appropriate medicines for neonates.
When excipients cannot be avoided, professionals should
have access to quantitative and qualitative information
that allows them to assess risk and monitor vulnerable
patients appropriately.
Competing interests
None of the authors declares any competing interest.
Authors’ contributions
JL, RK and HV carried out the data collection. JL and IL participated in the
design of the study. JL and IL performed the analysis. KN, MT, US and IL
drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgements
MAT, US, HV and IL work on the European Study of Neonatal Excipient
Exposure project funded through the PRIOMEDCHILD initiative by the
Estonian Science Foundation and UK Medical Research Council.
JL and IL was also supported by the Estonian Target Financing No. 2726.
Author details
1Institute of Microbiology, Tartu University, Tartu, Estonia. 2Pharmacy
Department, Tartu University Hospital, Tartu, Estonia. 3Department of
Pharmaceutics and Analytical Chemistry, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen, Denmark. 4Cheshire,
Merseyside & North Wales LRN, Medicines for Children Research Network,
Alder Hey Children's NHS Foundation Trust, Liverpool, UK. 5Tallinn Children’s
Hospital, Tallinn, Estonia. 6Children’s Clinic, Estonia Neonatal Unit, Tartu
University Hospital, Tartu, Estonia. 7University of Liverpool, Liverpool, UK.
8Neonatal Unit, Liverpool Women’s Hospital, Liverpool, UK.
Received: 27 March 2012 Accepted: 21 August 2012
Published: 29 August 2012
References
1. American Academy of Pediatrics, Committee on Drugs: Inactive ingredients
in pharmaceutical products: update (subject review). Pediatrics 1997,
99:268–278.
2. Hall C, Milligan D, Berrington J: Probable adverse reaction to a
pharmaceutical excipient. Arch Dis Child Fetal Neonatal Ed 2004, 89(2):F184.
3. Masi S, Cléty D, Clément S, Anslot C, Detaille T: Acute amiodarone toxicity
due to an administration error: could excipient be responsible? Br J Clin
Pharmacol 2009, 67(6):691–693.
4. Peleg O, Bar-Oz B, Arad I: Coma in a premature infant associated with the
transdermal absorption of propylene glycol. Acta Paediatrica 1998, 87
(11):1195–1196.
5. DeMerlis CC, Goldring JM, Velagaleti R, Brock W, Osterberg R: Regulatory
Update: The IPEC Novel Excipient Safety Evaluation Procedure. Pharm
Technol 2009, 33(11):72–82.
6. Food and Drug Administration: Guidance for Industry Nonclinical Safety
Evaluation of Pediatric Drug Products. 2006. http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.
pdf. Accessed November, 14, 2011.
7. European Medicines Agency, Committee for Medicinal Products for Human
Use (CHMP): Guideline on excipients in the dossier for application for marketing
authorisation of a medicinal product 2007. CHMP/QWP/396951/06.
8. European Medicines Agency, Committee for Medicinal Products for Human
Use (CHMP): Reflection paper: Formulations of choice for the paediatric
population. 2006. http://www.emea.europa.eu/pdfs/human/paediatrics/
19481005en.pdf. Accessed August, 11, 2011.
9. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman
RE: Developmental pharmacology-drug disposition, action, and therapy
in infants and children. N Engl J Med 2003, 349(12):1157–1167.
Lass et al. BMC Pediatrics 2012, 12:136 Page 10 of 11
http://www.biomedcentral.com/1471-2431/12/136
10. Phelps DL: E-Ferol: What happened and what now? Paediatrics 1984,
74:1114–1116.
11. Tuleu C: Paediatric formulation in practice. In Paediatric drug handling.
firstth edition. Edited by Costello I, Long PF, Wong I, Tuleu C, Yeung V.
London: Pharmaceutical Press; 2007:43.
12. Golightly LK, Smolinske SS, Bennett ML, Sutherland EW 3rd: Rumack BH.
Pharmaceutical excipients. Adverse effects associated with inactive
ingredients in drug products (Part I). Medical Toxicology and Adverse Drug
Experience 1988, 3:128–165.
13. Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC: Toxic
additives in medication for preterm infants. Arch Dis Child Fetal Neonatal
Ed 2009, 94(4):F236–F240.
14. Ursino MG, Poluzzi E, Caramella C, Ponti FD: Excipients in medicinal
products used in gastroenterology as a possible cause of side effects.
Regul Toxicol Pharmacol 2011, 60:93–105.
15. Standing JF, Tuleu C: Paediatric formulations—Getting to the heart of the
problem. Int J Pharm 2005, 300(1–2):56–66.
16. Shehab N, Lewis CL, Streetman DD, Donn SM: Exposure to the
pharmaceutical excipients benzyl alcohol and propylene glycol among
critically ill neonates. Pediatr Crit Care Med 2009, 10(2):256–259.
17. Lass J, Käär R, Jõgi K, Varendi H, Metsvaht T, Lutsar I: Drug utilisation
pattern and off-label use of medicines in Estonian neonatal units. Eur J
Clin Pharmacol 2011, 67:1263–1271.
18. Rowe RC, Sheskey PJ, Quinn ME: Handbook of pharmaceutical excipients. 6th
edition. London: Pharmaceutical Press; 2009.
19. European Commission: The Rules Governing Medicinal Products in the
European Union. Excipients in the Label and Package leaflet of Medicinal
Products for Human Use. 2003. http://pharmacos.eudra.org/F2/eudralex/vol-
3/pdfs-en/3bc7a_200307en.pdf. Accessed August, 2011, 2011.
20. Fabiano V, Mameli C, Zuccotti GV: Paediatric pharmacology: Remember
the excipients. Pharmacol Res 2011, 63:362–365.
21. Costello I, Long PF, Wong IK, Tuleu C, Yeung V (Eds): Paediatric Drug
Handling. Great Britain: Pharmaceutical Press; 2007.
22. Solà R, Boj M, Hernandez-Flix S, Camprubí M: Silica in oral drugs as a
possible sarcoidosis-inducing antigen. Lancet 2009, 373(9679):1943–1944.
23. Singh M, Winhoven S, Beck M: Contact sensitivity to octyldodecanol and
trometamol in an anti-itch cream. Contact Derm 2007, 56(5):289–290.




+Monograph&spell=1&biw. Accessed September, 8, 2011.
25. Braun S, Werdehausen R, Gaza N, Hermanns H, Kremer D, Küry P, et al:
Benzethonium increases the cytotoxicity of (S)-ketamine in lymphoma,
neuronal, and glial cells. Anesth Analg 2010, 111(6):1389–1393.
26. Mpountoukas P, Pantazaki A, Kostareli E, Christodoulou P, Kareli D,
Poliliou S, et al: Cytogenetic evaluation and DNA interaction studies
of the food colorants amaranth, erythrosine and tartrazine. Food
Chem Toxicol 2010, 48(10):2934–2944.
27. Asakawa H, Araki T, Yamamoto N, Imai I, Yamane M, Tsutsumi Y, et al:
Allergy to ethylenediamine and steroid. J Investig Allergol Clin Immunol
2000, 10(6):372–374.
28. van Riet-Nales DA, de Jager KE, Schobben AFAM, Egberts TCG, Rademaker
C: The availability and age-appropriateness of medicines authorized for
children in the Netherlands. Br J Clin Pharmacol 2011, 72(3):465–473.
29. Allegaert K, Vanhaesebrouck S, Kulo A, Cosaert K, Verbesselt R, Debeer A, et
al: Prospective assessment of short-term propylene glycol tolerance in
neonates. Arch Dis Child 2010, 95(12):1054–1058.
30. Cram A, Breitkreutz J, Desset-Brèthes S, Nunn T, Tuleu C: Challenges of
developing palatable oral paediatric formulations. Int J Pharm 2009, 365
(1–2):1–3.
31. Yakkundi S, McElnay J, Millership J, Mulla H, Pandya H, Shah U, et al: Use of
dried blood spots to study excipient kinetics in neonates. Bioanalysis
2011, 3(24):2691–2693.
doi:10.1186/1471-2431-12-136
Cite this article as: Lass et al.: Hospitalised neonates in Estonia
commonly receive potentially harmful excipients. BMC Pediatrics 2012
12:136.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lass et al. BMC Pediatrics 2012, 12:136 Page 11 of 11
http://www.biomedcentral.com/1471-2431/12/136
